B+
Bull case
25%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
DRTS
Alpha Tau MedicalFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The bull case is that Japan approval, multiple U.S. trials running in parallel, and several 2026 recruitment/readout checkpoints begin to convert Alpha DaRT from a concept stock into a platform with repeatable clinical and regulatory validation; cash of $76.9 million and management's stated at-least-two-year runway reduce immediate financing pressure [#PR-2026-03-09] [#20F-2026-03-09].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Japan approval still requires post-market surveillance and reimbursement work before commercial contribution is visible.
Momentum
47
Value
36
Sentiment
22
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $10.50 · Bear $5.00Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $17.80
Why
Momentum47 · Δ7d -17.5
Value36 · Δ7d +0.0
Sentiment22 · Δ7d -3.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.0.
Contradictions & invalidation
- • Japan approval still requires post-market surveillance and reimbursement work before commercial contribution is visible.
- • Key 2026 milestones are mostly enrollment/readout checkpoints rather than revenue events, so delays can hurt sentiment quickly.
- • The bear case is that DRTS still has no broad commercial revenue base, relies on preliminary clinical datasets, and its own 20-F says it will need substantial additional funding over time as trials, manufacturing scale-up, and commercialization spending rise; any slippage in enrollment, safety, or reimbursement could quickly re-rate the story lower [#20F-2026-03-09].
Catalyst clock
2026-05-02
DDW 2026 pancreatic data presentation
Lead driver: Value · See fundamentals
Momentum
47
8% active weight
Current posture
7d trendImproving
Δ7d
-17.5
Δ21d
-33.4
Value
36
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
22
45% active weight
Current posture
7d trendSoftening
Δ7d
-3.7
Δ21d
+6.2
Why this grade
Composite grade F. Momentum 46.9 / Value 36.3 / Sentiment 21.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.22B
Beta
1.04
Shares Out
92.48M
P/E (TTM) · Derived
-24.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-31.61
Rev YoY
-
EPS YoY
+301.4%
Gross Margin
-
Op Margin
-
Net Debt
-$63.18M
Current Ratio
11.09
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data